Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
General Review Article

An Update on the Neurochemistry of Essential Tremor

Author(s): Félix Javier Jiménez-Jiménez *, Hortensia Alonso-Navarro, Elena García-Martín and José A.G. Agúndez

Volume 27, Issue 10, 2020

Page: [1690 - 1710] Pages: 21

DOI: 10.2174/0929867325666181112094330

Price: $65

Abstract

Background: The pathophysiology and neurochemical mechanisms of essential tremor (ET) are not fully understood, because only a few post-mortem studies have been reported, and there is a lack of good experimental model for this disease.

Objective: The main aim of this review is to update data regarding the neurochemical features of ET. Alterations of certain catecholamine systems, the dopaminergic, serotonergic, GABAergic, noradrenergic, and adrenergic systems have been described, and are the object of this revision.

Methods: For this purpose, we performed a literature review on alterations of the neurotransmitter or neuromodulator systems (catecholamines, gammaaminobutyric acid or GABA, excitatory amino acids, adenosine, T-type calcium channels) in ET patients (both post-mortem or in vivo) or in experimental models resembling ET.

Results and Conclusion: The most consistent data regarding neurochemistry of ET are related with the GABAergic and glutamatergic systems, with a lesser contribution of adenosine and dopaminergic and adrenergic systems, while there is not enough evidence of a definite role of other neurotransmitter systems in ET. The improvement of harmaline-induced tremor in rodent models achieved with T-type calcium channel antagonists, cannabinoid 1 receptor, sphingosine-1-phosphate receptor agonists, and gap-junction blockers, suggests a potential role of these structures in the pathogenesis of ET.

Keywords: Essential tremor, neurochemistry, GABA, glutamate, dopamine, noradrenaline, adrenaline, serotonin, adenosine, T-type calcium channels.

« Previous
[1]
Rajput, A.H.; Rozdilsky, B.; Kish, S.; Hornykiewicz, O. Parkinson’s disease association with essential tremor. Mov. Disord., 1990, 5(Suppl. 1), 14.
[2]
Shill, H.A.; Adler, C.H.; Beach, T.G.; Lue, L.F.; Caviness, J.N.; Sabbagh, M.N.; Sue, L.I.; Walker, D.G. Brain biochemistry in autopsied patients with essential tremor. Mov. Disord., 2012, 27(1), 113-117.
[http://dx.doi.org/10.1002/mds.24004] [PMID: 22038525]
[3]
Lee, M.S.; Kim, Y.D. Im, J.H.; Kim, H.J.; Rinne, J.O.; Bhatia, K.P. 123I-IPT brain study in essential tremor and Parkinson’s disease. Neurology, 1999, 52, 1422-1426.
[http://dx.doi.org/10.1212/WNL.52.7.1422] [PMID: 10227629]
[4]
Plotkin, M.; Amthauer, H.; Klaffke, S.; Kühn, A.; Lüdemann, L.; Arnold, G.; Wernecke, K.D.; Kupsch, A.; Felix, R.; Venz, S. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J. Neural Transm. (Vienna), 2005, 112(5), 677-692.
[http://dx.doi.org/10.1007/s00702-004-0208-x] [PMID: 15375677]
[5]
Isaias, I.U.; Marotta, G.; Hirano, S.; Canesi, M.; Benti, R.; Righini, A.; Tang, C.; Cilia, R.; Pezzoli, G.; Eidelberg, D.; Antonini, A. Imaging essential tremor. Mov. Disord., 2010, 25(6), 679-686.
[http://dx.doi.org/10.1002/mds.22870] [PMID: 20437537]
[6]
Benamer, T.S.; Patterson, J.; Grosset, D.G.; Booij, J.; de Bruin, K.; van Royen, E.; Speelman, J.D.; Horstink, M.H.; Sips, H.J.; Dierckx, R.A.; Versijpt, J. Decoo. D; Van Der Linden, C.; Hadley, D.M.; Doder, M.; Lees, A.J.; Costa, D.C.; Gacinovic, S.; Oertel, W.H.; Pogarel,l O.; Hoeffken, H.; Joseph. K.; Tatsch, K.; Schwarz, J.; Ries, V. Accurate differentiation of parkinsonism and essential tremor using visual assessment of 123I-FP-CIT-SPECT imaging: the 123I-FP-CIT-SPECT study group. Mov. Disord., 2000, 15, 503-510.
[http://dx.doi.org/10.1002/1531-8257(200005)15:3<503:AID-MDS1013>3.0.CO;2-V]
[7]
Wang, J.; Jiang, Y.P.; Liu, X.D.; Chen, Z.P.; Yang, L.Q.; Liu, C.J.; Xiang, J.D.; Su, H.L. 99mTc-TRODAT-1 SPECT study in early Parkinson’s disease and essential tremor. Acta Neurol. Scand., 2005, 112(6), 380-385.
[http://dx.doi.org/10.1111/j.1600-0404.2005.00517.x] [PMID: 16281920]
[8]
Antonini, A.; Moresco, R.M.; Gobbo, C.; De Notaris, R.; Panzacchi, A.; Barone, P.; Calzetti, S.; Negrotti, A.; Pezzoli, G.; Fazio, F. The status of dopamine nerve terminals in Parkinson’s disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. Neurol. Sci., 2001, 22(1), 47-48.
[http://dx.doi.org/10.1007/s100720170040] [PMID: 11487195]
[9]
Breit, S.; Reimold, M.; Reischl, G.; Klockgether, T.; Wüllner, U. [(11)C]d-threo-methylphenidate PET in patients with Parkinson’s disease and essential tremor. J. Neural Transm. (Vienna), 2006, 113(2), 187-193.
[http://dx.doi.org/10.1007/s00702-005-0311-7] [PMID: 15959851]
[10]
Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology, 2000, 55(10), 1540-1547.
[http://dx.doi.org/10.1212/WNL.55.10.1540] [PMID: 11094111]
[11]
Di Giuda, D.; Camardese, G.; Bentivoglio, A.R.; Cocciolillo, F.; Guidubaldi, A.; Pucci, L.; Bruno, I.; Janiri, L.; Giordano, A.; Fasano, A. Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(12), 1937-1948.
[http://dx.doi.org/10.1007/s00259-012-2232-7] [PMID: 22976499]
[12]
Waln, O.; Wu, Y.; Perlman, R.; Wendt, J.; Van, A.K.; Jankovic, J. Dopamine transporter imaging in essential tremor with and without parkinsonian features. J. Neural Transm. (Vienna), 2015, 122(11), 1515-1521.
[http://dx.doi.org/10.1007/s00702-015-1419-z] [PMID: 26133163]
[13]
Barbagallo, G.; Arabia, G.; Morelli, M.; Nisticò, R.; Novellino, F.; Salsone, M.; Rocca, F.; Quattrone, A.; Caracciolo, M.; Sabatini, U.; Cherubini, A.; Quattrone, A. Thalamic neurometabolic alterations in tremulous Parkinson’s disease: A preliminary proton MR spectroscopy study. Parkinsonism Relat. Disord., 2017, 43, 78-84.
[http://dx.doi.org/10.1016/j.parkreldis.2017.07.028] [PMID: 28774469]
[14]
Brooks, D.J.; Playford, E.D.; Ibanez, V.; Sawle, G.V.; Thompson, P.D.; Findley, L.J.; Marsden, C.D. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology, 1992, 42(8), 1554-1560.
[http://dx.doi.org/10.1212/WNL.42.8.1554] [PMID: 1641153]
[15]
Asenbaum, S.; Pirker, W.; Angelberger, P.; Bencsits, G.; Pruckmayer, M.; Brücke, T. [123I]beta-CIT and SPECT in essential tremor and Parkinson’s disease. J. Neural Transm. (Vienna), 1998, 105(10-12), 1213-1228.
[http://dx.doi.org/10.1007/s007020050124] [PMID: 9928890]
[16]
Gerasimou, G.; Costa, D.C.; Papanastasiou, E.; Bostanjiopoulou, S.; Arnaoutoglou, M.; Moralidis, E.; Aggelopoulou, T.; Gotzamani-Psarrakou, A. SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson’s disease? Ann. Nucl. Med., 2012, 26(4), 337-344.
[http://dx.doi.org/10.1007/s12149-012-0577-4] [PMID: 22382608]
[17]
Isaias, I.U.; Canesi, M.; Benti, R.; Gerundini, P.; Cilia, R.; Pezzoli, G.; Antonini, A. Striatal dopamine transporter abnormalities in patients with essential tremor. Nucl. Med. Commun., 2008, 29(4), 349-353.
[http://dx.doi.org/10.1097/MNM.0b013e3282f4d307] [PMID: 18317299]
[18]
Ceravolo, R.; Antonini, A.; Volterrani, D.; Rossi, C.; Kiferle, L.; Frosini, D.; Lucetti, C.; Isaias, I.U.; Benti, R.; Murri, L.; Bonuccelli, U. Predictive value of nigrostriatal dysfunction in isolated tremor: a clinical and SPECT study. Mov. Disord., 2008, 23(14), 2049-2054.
[http://dx.doi.org/10.1002/mds.22259] [PMID: 18759337]
[19]
Coria, F.; Gimenez-Garcia, M.; Samaranch, L.; Mora, F.J.; Sampol-Bas, C.; Pastor, P. Nigrostriatal dopaminergic function in subjects with isolated action tremor. Parkinsonism Relat. Disord., 2012, 18(1), 49-53.
[http://dx.doi.org/10.1016/j.parkreldis.2011.08.025] [PMID: 21917500]
[20]
Pirker, W.; Djamshidian, S.; Asenbaum, S.; Gerschlager, W.; Tribl, G.; Hoffmann, M.; Brücke, T. Progression of dopaminergic degeneration in Parkinson’s disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov. Disord., 2002, 17(1), 45-53.
[http://dx.doi.org/10.1002/mds.1265] [PMID: 11835438]
[21]
Schwartz, M.; Groshar, D.; Inzelberg, R.; Hocherman, S. Dopamine-transporter imaging and visuo-motor testing in essential tremor, practical possibilities for detection of early stage Parkinson’s disease. Parkinsonism Relat. Disord., 2004, 10(6), 385-389.
[http://dx.doi.org/10.1016/j.parkreldis.2004.03.004] [PMID: 15261882]
[22]
Lenman, J.A.; Turnbull, M.J.; Reid, A.; Fleming, A.M. Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa. J. Neurol. Sci., 1977, 32(2), 219-225.
[http://dx.doi.org/10.1016/0022-510X(77)90237-4] [PMID: 874521]
[23]
Pellicano, C.; Buttarelli, F.R.; Circella, A.; Tiple, D.; Giovannelli, M.; Benincasa, D.; Colosimo, C.; Pontieri, F.E. Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson’s disease from essential tremor. J. Neural Transm. (Vienna), 2007, 114(7), 935-938.
[http://dx.doi.org/10.1007/s00702-006-0623-2] [PMID: 17260170]
[24]
Schwartz, M.; Badarny, S.; Gofman, S.; Hocherman, S. Visuomotor performance in patients with essential tremor. Mov. Disord., 1999, 14(6), 988-993.
[http://dx.doi.org/10.1002/1531-8257(199911)14:6<988:AID-MDS1012>3.0.CO;2-M] [PMID: 10584674]
[25]
Jiménez-Jiménez, F.J.; Rubio, L.; Alonso-Navarro, H.; Calleja, M.; Pilo-de-la-Fuente, B.; Plaza-Nieto, J.F.; Benito-León, J.; García-Ruiz, P.J.; Agúndez, J.A. Impairment of rapid repetitive finger movements and visual reaction time in patients with essential tremor. Eur. J. Neurol., 2010, 17(1), 152-159.
[http://dx.doi.org/10.1111/j.1468-1331.2009.02784.x] [PMID: 19765055]
[26]
Pedrosa, D.J.; Nelles, C.; Maier, F.; Eggers, C.; Burghaus, L.; Fink, G.R.; Wittmann, M.; Timmermann, L. Time reproduction deficits in essential tremor patients. Mov. Disord., 2016, 31(8), 1234-1240.
[http://dx.doi.org/10.1002/mds.26630] [PMID: 27091412]
[27]
Lucotte, G.; Lagarde, J.P.; Funalot, B.; Sokoloff, P. Linkage with the Ser9Gly DRD3 polymorphism in essential tremor families. Clin. Genet., 2006, 69(5), 437-440.
[http://dx.doi.org/10.1111/j.1399-0004.2006.00600.x] [PMID: 16650084]
[28]
Jeanneteau, F.; Funalot, B.; Jankovic, J.; Deng, H.; Lagarde, J.P.; Lucotte, G.; Sokoloff, P. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc. Natl. Acad. Sci. USA, 2006, 103(28), 10753-10758.
[http://dx.doi.org/10.1073/pnas.0508189103] [PMID: 16809426]
[29]
García-Martín, E.; Martínez, C.; Alonso-Navarro, H.; Benito-León, J.; Puertas, I.; Rubio, L.; López-Alburquerque, T.; Agúndez, J.A.; Jiménez-Jiménez, F.J. Dopamine receptor D3 (DRD3) genotype and allelic variants and risk for essential tremor. Mov. Disord., 2009, 24(13), 1910-1915.
[http://dx.doi.org/10.1002/mds.22518] [PMID: 19645064]
[30]
Jiménez-Jiménez, F.J.; Alonso-Navarro, H.; García-Martín, E.; Lorenzo-Betancor, O.; Pastor, P.; Agúndez, J.A. Update on genetics of essential tremor. Acta Neurol. Scand., 2013, 128(6), 359-371.
[http://dx.doi.org/10.1111/ane.12148] [PMID: 23682623]
[31]
Mao, X.; Wang, T.; Liu, M.; Chang, X.; Li, N.; Gu, Y.; Zhao, D.; Liao, Q.; Peng, R. Meta-analysis of the influence of DRD3 Ser9Gly variant on susceptibility for essential tremor. J. Clin. Neurosci., 2013, 20(12), 1644-1649.
[http://dx.doi.org/10.1016/j.jocn.2013.03.023] [PMID: 24054403]
[32]
Kuhlenbäumer, G.; Hopfner, F.; Deuschl, G. Genetics of essential tremor: meta-analysis and review. Neurology, 2014, 82(11), 1000-1007.
[http://dx.doi.org/10.1212/WNL.0000000000000211] [PMID: 24532269]
[33]
Jiménez-Jiménez, F.J.; García-Martín, E.; Alonso-Navarro, H.; Lorenzo-Betancor, O.; Ortega-Cubero, S.; Pastor, P.; Calleja, M.; Agúndez, J.A. A family study of DRD3 rs6280, SLC1A2 rs3794087 and MAPT rs1052553 variants in essential tremor. Neurol. Res., 2016, 38(10), 880-887.
[http://dx.doi.org/10.1080/01616412.2016.1210355] [PMID: 27456607]
[34]
Ossowska, K.; Głowacka, U.; Kosmowska, B.; Wardas, J. Apomorphine enhances harmaline-induced tremor in rats. Pharmacol. Rep., 2015, 67(3), 435-441.
[http://dx.doi.org/10.1016/j.pharep.2014.11.008] [PMID: 25933950]
[35]
Herceg, M.; Nagy, F.; Pál, E.; Janszky, J.; Késmárky, I.; Komoly, S.; Kovács, N. Pramipexole may be an effective treatment option in essential tremor. Clin. Neuropharmacol., 2012, 35(2), 73-76.
[http://dx.doi.org/10.1097/WNF.0b013e31824687bf] [PMID: 22318193]
[36]
Kosmowska, B.; Wardas, J.; Głowacka, U.; Ananthan, S.; Ossowska, K. Pramipexole at a low dose induces beneficial effect in the harmaline-induced model of essential tremor in rats. CNS Neurosci. Ther., 2016, 22(1), 53-62.
[http://dx.doi.org/10.1111/cns.12467] [PMID: 26459182]
[37]
Rajput, A.H.; Hornykiewicz, O.; Deng, Y.; Birdi, S.; Miyashita, H.; Macaulay, R. Increased noradrenaline levels in essential tremor brain. Neurology, 2001, 56(Suppl. 3), A302.
[38]
Barkhatova, V.P.; Ivanova-Smolenskaia, I.A. [Catecholamine metabolism in essential tremor]. Zh. Nevropatol. Psikhiatr. Im. S. S. Korsakova, 1990, 90(3), 10-14.
[PMID: 2163146]
[39]
van Hilten, J.J.; van Dijk, J.G.; Dunnewold, R.J.; van der Velde, E.A.; Kemp, B.; van Brummelen, P.; van der Krogt, J.A.; Roos, R.A.; Buruma, O.J. Diurnal variation of essential and physiological tremor. J. Neurol. Neurosurg. Psychiatry, 1991, 54(6), 516-519.
[http://dx.doi.org/10.1136/jnnp.54.6.516] [PMID: 1880513]
[40]
Tapiador, M.J.; Pérez López-Fraile, I.; López-López, A. Temblor esencial: una revisión sobre sus mecanismos patogénicos. Rev. Neurol., 1998, 27(160), 1059-1065.
[http://dx.doi.org/10.33588/rn.27160.98212] [PMID: 9951036]
[41]
Lee, P.H.; Kim, J.W.; Bang, O.Y.; Joo, I.S.; Yoon, S.N.; Huh, K. Cardiac 123I-MIBG scintigraphy in patients with essential tremor. Mov. Disord., 2006, 21(8), 1235-1238.
[http://dx.doi.org/10.1002/mds.20908] [PMID: 16671077]
[42]
Marsden, C.D.; Foley, T.H.; Owen, D.A.L.; McAllister, R.G. Peripheral beta-adrenergic receptors concerned with tremor. Clin. Sci., 1967, 33(1), 53-65.
[PMID: 6059304]
[43]
Jefferson, D.; Jenner, P.; Marsden, C.D. beta-Adrenoreceptor antagonists in essential tremor. J. Neurol. Neurosurg. Psychiatry, 1979, 42(10), 904-909.
[http://dx.doi.org/10.1136/jnnp.42.10.904] [PMID: 512665]
[44]
Young, R.R.; Growdon, J.H.; Shahani, B.T. Beta-adrenergic mechanisms in action tremor. N. Engl. J. Med., 1975, 293(19), 950-953.
[http://dx.doi.org/10.1056/NEJM197511062931902] [PMID: 1178003]
[45]
Leigh, P.N.; Marsden, C.D.; Twomey, A.; Jefferson, D. beta-Adrenoceptor antagonists and essential tremor. Lancet, 1981, 1(8229), 1106.
[http://dx.doi.org/10.1016/S0140-6736(81)92276-5] [PMID: 6112475]
[46]
Teräväinen, H.; Larsen, T.A. Adrenergic beta-receptor sensitivity in essential tremor. J. Neurol. Neurosurg. Psychiatry, 1984, 47(11), 1216-1218.
[http://dx.doi.org/10.1136/jnnp.47.11.1216] [PMID: 6094733]
[47]
Koller, W.C. Tradozone in essential tremor. Probe of serotoninergic mechanisms. Clin. Neuropharmacol., 1989, 12(2), 134-137.
[http://dx.doi.org/10.1097/00002826-198904000-00009] [PMID: 2655897]
[48]
Gironell, A.; Figueiras, F.P.; Pagonabarraga, J.; Herance, J.R.; Pascual-Sedano, B.; Trampal, C.; Gispert, J.D. Gaba and serotonin molecular neuroimaging in essential tremor: a clinical correlation study. Parkinsonism Relat. Disord., 2012, 18(7), 876-880.
[http://dx.doi.org/10.1016/j.parkreldis.2012.04.024] [PMID: 22595620]
[49]
Abdulrahman, A.A.; Faisal, K.; Meshref, A.A.; Arshaduddin, M. Low-dose acute vanillin is beneficial against harmaline-induced tremors in rats. Neurol. Res., 2017, 39(3), 264-270.
[http://dx.doi.org/10.1080/01616412.2016.1275456] [PMID: 28095756]
[50]
Zoethout, R.W.; Iannone, R.; Bloem, B.R.; Palcza, J.; Murphy, G.; Chodakewitz, J.; Buntinx, A.; Gottesdiener, K.; Marsilio, S.; Rosen, L.; van Dyck, K.; Louis, E.D.; Cohen, A.F.; Schoemaker, R.C.; Tokita, S.; Sato, N.; Koblan, K.S.; Hargreaves, R.H.; Renger, J.; van Gerven, J.M. The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol. J. Psychopharmacol. (Oxford), 2012, 26(2), 292-302.
[http://dx.doi.org/10.1177/0269881111398685] [PMID: 21335358]
[51]
Ledesma, M.C.; García-Martín, E.; Alonso-Navarro, H.; Martínez, C.; Jiménez-Jiménez, F.J.; Benito-León, J.; Puertas, I.; Rubio, L.; López-Alburquerque, T.; Agúndez, J.A. The nonsynonymous Thr105Ile polymorphism of the histamine N-methyltransferase is associated to the risk of developing essential tremor. Neuromolecular Med., 2008, 10(4), 356-361.
[http://dx.doi.org/10.1007/s12017-008-8040-3] [PMID: 18543121]
[52]
Keeling, B.H.; Vilariño-Güell, C.; Soto-Ortolaza, A.I.; Ross, O.A.; Uitti, R.J.; Rajput, A.; Wszolek, Z.K.; Farrer, M.J. Histamine N-methyltransferase Thr105Ile is not associated with Parkinson’s disease or essential tremor. Parkinsonism Relat. Disord., 2010, 16(2), 112-114.
[http://dx.doi.org/10.1016/j.parkreldis.2009.08.011] [PMID: 19773194]
[53]
Pahapill, P.A.; Levy, R.; Dostrovsky, J.O.; Davis, K.D.; Rezai, A.R.; Tasker, R.R.; Lozano, A.M. Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor. Ann. Neurol., 1999, 46(2), 249-252.
[http://dx.doi.org/10.1002/1531-8249(199908)46:2<249:AID-ANA15>3.0.CO;2-C] [PMID: 10443891]
[54]
Tariq, M.; Arshaduddin, M.; Biary, N.; Al Moutaery, K.; Al Deeb, S. Baclofen attenuates harmaline induced tremors in rats. Neurosci. Lett., 2001, 312(2), 79-82.
[http://dx.doi.org/10.1016/S0304-3940(01)02166-8] [PMID: 11595339]
[55]
de Haas, S.L.; Zoethout, R.W.; Van Dyck, K.; De Smet, M.; Rosen, L.B.; Murphy, M.G.; Gottesdiener, K.M.; Schoemaker, R.C.; Cohen, A.F.; van Gerven, J.M. The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol. J. Psychopharmacol. (Oxford), 2012, 26(2), 282-291.
[http://dx.doi.org/10.1177/0269881111415731] [PMID: 21890585]
[56]
Málly, J.; Stone, T.W. The effect of theophylline on essential tremor: the possible role of GABA. Pharmacol. Biochem. Behav., 1991, 39(2), 345-349.
[http://dx.doi.org/10.1016/0091-3057(91)90190-D] [PMID: 1946576]
[57]
Málly, J.; Baranyi, M.; Vizi, E.S. Change in the concentrations of amino acids in CSF and serum of patients with essential tremor. J. Neural Transm. (Vienna), 1996, 103(5), 555-560.
[http://dx.doi.org/10.1007/BF01273153] [PMID: 8811501]
[58]
Paris-Robidas, S.; Brochu, E.; Sintes, M.; Emond, V.; Bousquet, M.; Vandal, M.; Pilote, M.; Tremblay, C.; Di Paolo, T.; Rajput, A.H.; Rajput, A.; Calon, F. Defective dentate nucleus GABA receptors in essential tremor. Brain, 2012, 135(Pt 1), 105-116.
[http://dx.doi.org/10.1093/brain/awr301] [PMID: 22120148]
[59]
Luo, C.; Rajput, A.H.; Robinson, C.A.; Rajput, A. Gamma-aminobutyric acid (GABA)-B receptor 1 in cerebellar cortex of essential tremor. J. Clin. Neurosci., 2012, 19(6), 920-921.
[http://dx.doi.org/10.1016/j.jocn.2011.11.001] [PMID: 22321358]
[60]
Boecker, H.; Weindl, A.; Brooks, D.J.; Ceballos-Baumann, A.O.; Liedtke, C.; Miederer, M.; Sprenger, T.; Wagner, K.J.; Miederer, I. GABAergic dysfunction in essential tremor: an 11C-flumazenil PET study. J. Nucl. Med., 2010, 51(7), 1030-1035.
[http://dx.doi.org/10.2967/jnumed.109.074120] [PMID: 20554735]
[61]
Louis, E.D.; Hernandez, N.; Dyke, J.P.; Ma, R.E.; Dydak, U. In vivo dentate nucleus gamma-aminobutyric acid concentration in essential tremor vs. controls. Cerebellum, 2018, 17(2), 165-172.
[http://dx.doi.org/10.1007/s12311-017-0891-4] [PMID: 29039117]
[62]
Kralic, J.E.; Criswell, H.E.; Osterman, J.L.; O’Buckley, T.K.; Wilkie, M.E.; Matthews, D.B.; Hamre, K.; Breese, G.R.; Homanics, G.E.; Morrow, A.L. Genetic essential tremor in gamma-aminobutyric acidA receptor alpha1 subunit knockout mice. J. Clin. Invest., 2005, 115(3), 774-779.
[http://dx.doi.org/10.1172/JCI200523625] [PMID: 15765150]
[63]
Deng, H.; Xie, W.J.; Le, W.D.; Huang, M.S.; Jankovic, J. Genetic analysis of the GABRA1 gene in patients with essential tremor. Neurosci. Lett., 2006, 401(1-2), 16-19.
[http://dx.doi.org/10.1016/j.neulet.2006.02.066] [PMID: 16530959]
[64]
García-Martín, E.; Martínez, C.; Alonso-Navarro, H.; Benito-León, J.; Lorenzo-Betancor, O.; Pastor, P.; Puertas, I.; Rubio, L.; López-Alburquerque, T.; Agúndez, J.A.; Jiménez-Jiménez, F.J. Gamma-aminobutyric acid (GABA) receptor rho (GABRR) polymorphisms and risk for essential tremor. J. Neurol., 2011, 258(2), 203-211.
[http://dx.doi.org/10.1007/s00415-010-5708-z] [PMID: 20820800]
[65]
García-Martín, E.; Martínez, C.; Alonso-Navarro, H.; Benito-León, J.; Lorenzo-Betancor, O.; Pastor, P.; Puertas, I.; Rubio, L.; López-Alburquerque, T.; Agúndez, J.A.; Jiménez-Jiménez, F.J. Gamma-aminobutyric acid GABRA4, GABRE, and GABRQ receptor polymorphisms and risk for essential tremor. Pharmacogenet. Genomics, 2011, 21(7), 436-439.
[http://dx.doi.org/10.1097/FPC.0b013e328345bec0] [PMID: 21422964]
[66]
Thier, S.; Kuhlenbäumer, G.; Lorenz, D.; Nothnagel, M.; Nebel, A.; Christensen, K.; Schreiber, S.; Deuschl, G.; Klebe, S. GABA(A) receptor- and GABA transporter polymorphisms and risk for essential tremor. Eur. J. Neurol., 2011, 18(8), 1098-1100.
[http://dx.doi.org/10.1111/j.1468-1331.2010.03308.x] [PMID: 21749575]
[67]
Liu, X.; Hernandez, N.; Kisselev, S.; Floratos, A.; Sawle, A.; Ionita-Laza, I.; Ottman, R.; Louis, E.D.; Clark, L.N. Identification of candidate genes for familial early-onset essential tremor. Eur. J. Hum. Genet., 2016, 24(7), 1009-1015.
[http://dx.doi.org/10.1038/ejhg.2015.228] [PMID: 26508575]
[68]
Tio, M.; Wen, R.; Lim, Y.L.; Wang, H.; Ling, S.C.; Zhao, Y.; Tan, E.K. FUS-linked essential tremor associated with motor dysfunction in Drosophila. Hum. Genet., 2016, 135(11), 1223-1232.
[http://dx.doi.org/10.1007/s00439-016-1709-z] [PMID: 27395408]
[69]
Chuang, W.L.; Huang, Y.Z.; Lu, C.S.; Chen, R.S. Reduced cortical plasticity and GABAergic modulation in essential tremor. Mov. Disord., 2014, 29(4), 501-507.
[http://dx.doi.org/10.1002/mds.25809] [PMID: 24449142]
[70]
Lee, M.; Cheng, M.M.; Lin, C.Y.; Louis, E.D.; Faust, P.L.; Kuo, S.H. Decreased EAAT2 protein expression in the essential tremor cerebellar cortex. Acta Neuropathol. Commun., 2014, 2, 157.
[http://dx.doi.org/10.1186/s40478-014-0157-z] [PMID: 25391854]
[71]
Wang, J.; Kelly, G.C.; Tate, W.J.; Li, Y.S.; Lee, M.; Gutierrez, J.; Louis, E.D.; Faust, P.L.; Kuo, S.H. Excitatory Amino acid transporter expression in the essential tremor dentate nucleus and cerebellar cortex: A postmortem study. Parkinsonism Relat. Disord., 2016, 32, 87-93.
[http://dx.doi.org/10.1016/j.parkreldis.2016.09.003] [PMID: 27624392]
[72]
Lin, C.Y.; Louis, E.D.; Faust, P.L.; Koeppen, A.H.; Vonsattel, J.P.; Kuo, S.H. Abnormal climbing fibre-Purkinje cell synaptic connections in the essential tremor cerebellum. Brain, 2014, 137(Pt 12), 3149-3159.
[http://dx.doi.org/10.1093/brain/awu281] [PMID: 25273997]
[73]
Louis, E.D.; Shungu, D.C.; Chan, S.; Mao, X.; Jurewicz, E.C.; Watner, D. Metabolic abnormality in the cerebellum in patients with essential tremor: a proton magnetic resonance spectroscopic imaging study. Neurosci. Lett., 2002, 333(1), 17-20.
[http://dx.doi.org/10.1016/S0304-3940(02)00966-7] [PMID: 12401550]
[74]
Pagan, F.L.; Butman, J.A.; Dambrosia, J.M.; Hallett, M. Evaluation of essential tremor with multi-voxel magnetic resonance spectroscopy. Neurology, 2003, 60(8), 1344-1347.
[http://dx.doi.org/10.1212/01.WNL.0000065885.15875.0D] [PMID: 12707440]
[75]
Louis, E.D.; Shungu, D.C.; Mao, X.; Chan, S.; Jurewicz, E.C. Cerebellar metabolic symmetry in essential tremor studied with 1H magnetic resonance spectroscopic imaging: implications for disease pathology. Mov. Disord., 2004, 19(6), 672-677.
[http://dx.doi.org/10.1002/mds.20019] [PMID: 15197706]
[76]
Barbagallo, G.; Arabia, G.; Novellino, F.; Nisticò, R.; Salsone, M.; Morelli, M.; Rocca, F.; Quattrone, A.; Caracciolo, M.; Sabatini, U.; Cherubini, A.; Quattrone, A. Increased glutamate + glutamine levels in the thalamus of patients with essential tremor: A preliminary proton MR spectroscopic study. Parkinsonism Relat. Disord., 2018, 47, 57-63.
[http://dx.doi.org/10.1016/j.parkreldis.2017.11.345] [PMID: 29203059]
[77]
Manto, M.; Laute, M.A. A possible mechanism for the beneficial effect of ethanol in essential tremor. Eur. J. Neurol., 2008, 15(7), 697-705.
[http://dx.doi.org/10.1111/j.1468-1331.2008.02150.x] [PMID: 18445025]
[78]
Rahimi Shourmasti, F.; Goudarzi, I.; Lashkarbolouki, T.; Abrari, K.; Elahdadi Salmani, M.; Goudarzi, A. Effects of riluzole on harmaline induced tremor and ataxia in rats: biochemical, histological and behavioral studies. Eur. J. Pharmacol., 2012, 695(1-3), 40-47.
[http://dx.doi.org/10.1016/j.ejphar.2012.08.014] [PMID: 22975288]
[79]
Vaziri, Z.; Abbassian, H.; Sheibani, V.; Haghani, M.; Nazeri, M.; Aghaei, I.; Shabani, M. The therapeutic potential of Berberine chloride hydrate against harmaline-induced motor impairments in a rat model of tremor. Neurosci. Lett., 2015, 590, 84-90.
[http://dx.doi.org/10.1016/j.neulet.2015.01.078] [PMID: 25643620]
[80]
Ossowska, K.; Wardas, J.; Berghauzen-Maciejewska, K.; Głowacka, U.; Kuter, K.; Pilc, A.; Zorn, S.H.; Doller, D. Lu AF21934, a positive allosteric modulator of mGlu4 receptors, reduces the harmaline-induced hyperactivity but not tremor in rats. Neuropharmacology, 2014, 83, 28-35.
[http://dx.doi.org/10.1016/j.neuropharm.2014.03.018] [PMID: 24726309]
[81]
Thier, S.; Lorenz, D.; Nothnagel, M.; Poremba, C.; Papengut, F.; Appenzeller, S.; Paschen, S.; Hofschulte, F.; Hussl, A.C.; Hering, S.; Poewe, W.; Asmus, F.; Gasser, T.; Schöls, L.; Christensen, K.; Nebel, A.; Schreiber, S.; Klebe, S.; Deuschl, G.; Kuhlenbäumer, G. Polymorphisms in the glial glutamate transporter SLC1A2 are associated with essential tremor. Neurology, 2012, 79(3), 243-248.
[http://dx.doi.org/10.1212/WNL.0b013e31825fdeed] [PMID: 22764253]
[82]
Jiménez-Jiménez, F.J.; Alonso-Navarro, H.; García-Martín, E.; Agúndez, J.A. SLC1A2 rs3794087 variant and risk for essential tremor: a systematic review and meta-analysis. Pharmacogenet. Genomics, 2015, 25(11), 564-568.
[http://dx.doi.org/10.1097/FPC.0000000000000171] [PMID: 26313486]
[83]
Cheng, Y.; Mao, C.Y.; Liu, Y.T.; Li, F.; Yang, J.; Liu, H.; Zhang, C.; Wang, Y.L.; Wu, J.; Shi, C.H.; Xu, Y.M. Analysis of variant rs3794087 in SLC1A2 and Parkinson’s disease in a Chinese Han population: A case-control study and meta-analysis. Neurosci. Lett., 2018, 666, 165-168.
[http://dx.doi.org/10.1016/j.neulet.2017.12.045] [PMID: 29275184]
[84]
Bekar, L.; Libionka, W.; Tian, G.F.; Xu, Q.; Torres, A.; Wang, X.; Lovatt, D.; Williams, E.; Takano, T.; Schnermann, J.; Bakos, R.; Nedergaard, M. Adenosine is crucial for deep brain stimulation-mediated attenuation of tremor. Nat. Med., 2008, 14(1), 75-80.
[http://dx.doi.org/10.1038/nm1693] [PMID: 18157140]
[85]
Chang, S.Y.; Kim, I.; Marsh, M.P.; Jang, D.P.; Hwang, S.C.; Van Gompel, J.J.; Goerss, S.J.; Kimble, C.J.; Bennet, K.E.; Garris, P.A.; Blaha, C.D.; Lee, K.H. Wireless fast-scan cyclic voltammetry to monitor adenosine in patients with essential tremor during deep brain stimulation. Mayo Clin. Proc., 2012, 87(8), 760-765.
[http://dx.doi.org/10.1016/j.mayocp.2012.05.006] [PMID: 22809886]
[86]
Kosmowska, B.; Ossowska, K.; Głowacka, U.; Wardas, J. Tremorolytic effect of 5′-chloro-5′-deoxy-(±)-ENBA, a potent and selective adenosine A1 receptor agonist, evaluated in the harmaline-induced model in rats. CNS Neurosci. Ther., 2017, 23(5), 438-446.
[http://dx.doi.org/10.1111/cns.12692] [PMID: 28371468]
[87]
Park, Y.G.; Park, H.Y.; Lee, C.J.; Choi, S.; Jo, S.; Choi, H.; Kim, Y.H.; Shin, H.S.; Llinas, R.R.; Kim, D. Ca(V)3.1 is a tremor rhythm pacemaker in the inferior olive. Proc. Natl. Acad. Sci. USA, 2010, 107(23), 10731-10736.
[http://dx.doi.org/10.1073/pnas.1002995107] [PMID: 20498062]
[88]
Handforth, A.; Homanics, G.E.; Covey, D.F.; Krishnan, K.; Lee, J.Y.; Sakimura, K.; Martin, F.C.; Quesada, A. T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor. Neuropharmacology, 2010, 59(6), 380-387.
[http://dx.doi.org/10.1016/j.neuropharm.2010.05.012] [PMID: 20547167]
[89]
Chang, K.Y.; Park, Y.G.; Park, H.Y.; Homanics, G.E.; Kim, J.; Kim, D. Lack of CaV3.1 channels causes severe motor coordination defects and an age-dependent cerebellar atrophy in a genetic model of essential tremor. Biochem. Biophys. Res. Commun., 2011, 410(1), 19-23.
[http://dx.doi.org/10.1016/j.bbrc.2011.05.082] [PMID: 21621520]
[90]
Stefansson, H.; Steinberg, S.; Petursson, H.; Gustafsson, O.; Gudjonsdottir, I.H.; Jonsdottir, G.A.; Palsson, S.T.; Jonsson, T.; Saemundsdottir, J.; Bjornsdottir, G.; Böttcher, Y.; Thorlacius, T.; Haubenberger, D.; Zimprich, A.; Auff, E.; Hotzy, C.; Testa, C.M.; Miyatake, L.A.; Rosen, A.R.; Kristleifsson, K.; Rye, D.; Asmus, F.; Schöls, L.; Dichgans, M.; Jakobsson, F.; Benedikz, J.; Thorsteinsdottir, U.; Gulcher, J.; Kong, A.; Stefansson, K. Variant in the sequence of the LINGO1 gene confers risk of essential tremor. Nat. Genet., 2009, 41(3), 277-279.
[http://dx.doi.org/10.1038/ng.299] [PMID: 19182806]
[91]
Jiménez-Jiménez, F.J.; García-Martín, E.; Lorenzo-Betancor, O.; Pastor, P.; Alonso-Navarro, H.; Agúndez, J.A. LINGO1 and risk for essential tremor: results of a meta-analysis of rs9652490 and rs11856808. J. Neurol. Sci., 2012, 317(1-2), 52-57.
[http://dx.doi.org/10.1016/j.jns.2012.02.030] [PMID: 22425540]
[92]
Kuo, S.H.; Tang, G.; Louis, E.D.; Ma, K.; Babji, R.; Balatbat, M.; Cortes, E.; Vonsattel, J.P.; Yamamoto, A.; Sulzer, D.; Faust, P.L. Lingo-1 expression is increased in essential tremor cerebellum and is present in the basket cell pinceau. Acta Neuropathol., 2013, 125(6), 879-889.
[http://dx.doi.org/10.1007/s00401-013-1108-7] [PMID: 23543187]
[93]
Delay, C.; Tremblay, C.; Brochu, E.; Paris-Robidas, S.; Emond, V.; Rajput, A.H.; Rajput, A.; Calon, F. Increased LINGO1 in the cerebellum of essential tremor patients. Mov. Disord., 2014, 29(13), 1637-1647.
[http://dx.doi.org/10.1002/mds.25819] [PMID: 24531928]
[94]
Agúndez, J.A.; Jiménez-Jimenez, F.J.; Alonso-Navarro, H.; García-Martín, E. The potential of LINGO-1 as a therapeutic target for essential tremor. Expert Opin. Ther. Targets, 2015, 19(8), 1139-1148.
[http://dx.doi.org/10.1517/14728222.2015.1028360] [PMID: 25862159]
[95]
Hedera, P. Emerging strategies in the management of essential tremor. Ther. Adv. Neurol. Disorder., 2017, 10(2), 137-148.
[http://dx.doi.org/10.1177/1756285616679123] [PMID: 28382111]
[96]
Abbassian, H.; Whalley, B.J.; Sheibani, V.; Shabani, M. Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat. Br. J. Pharmacol., 2016, 173(22), 3196-3207.
[http://dx.doi.org/10.1111/bph.13581] [PMID: 27545646]
[97]
Abbassian, H.; Esmaeili, P.; Tahamtan, M.; Aghaei, I.; Vaziri, Z.; Sheibani, V.; Whalley, B.J.; Shabani, M. Cannabinoid receptor agonism suppresses tremor, cognition disturbances and anxiety-like behaviors in a rat model of essential tremor. Physiol. Behav, 2016, 164(Pt A), 314-320.
[http://dx.doi.org/10.1016/j.physbeh.2016.06.013] [PMID: 27317835]
[98]
Dahmardeh, N.; Asadi-Shekaari, M.; Arjmand, S.; Kalantaripour, T.; Basiri, M.; Shabani, M. Modulation of sphingosine-1-phosphate receptor ameliorates harmaline-induced essential tremor in rat. Neurosci. Lett., 2017, 653, 376-381.
[http://dx.doi.org/10.1016/j.neulet.2017.06.015] [PMID: 28627375]
[99]
Stroh, M.A.; Winter, M.K.; Swerdlow, R.H.; McCarson, K.E.; Zhu, H. Loss of NCB5OR in the cerebellum disturbs iron pathways, potentiates behavioral abnormalities, and exacerbates harmaline-induced tremor in mice. Metab. Brain Dis., 2016, 31(4), 951-964.
[http://dx.doi.org/10.1007/s11011-016-9834-x] [PMID: 27188291]
[100]
Martin, F.C.; Handforth, A. Carbenoxolone and mefloquine suppress tremor in the harmaline mouse model of essential tremor. Mov. Disord., 2006, 21(10), 1641-1649.
[http://dx.doi.org/10.1002/mds.20940] [PMID: 16773639]
[101]
Eder, U.; Leitner, B.; Kirchmair, R.; Pohl, P.; Jobst, K.A.; Smith, A.D.; Málly, J.; Benzer, A.; Riederer, P.; Reichmann, H.; Saria, A.; Winkler, H. Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases. J. Neural Transm. (Vienna), 1998, 105(1), 39-51.
[http://dx.doi.org/10.1007/s007020050036] [PMID: 9588759]
[102]
Alonso-Navarro, H.; Jiménez-Jiménez, F.J.; García-Martín, E.; Agúndez, J.A.G. Neurochemistry and neuropharmacology of essential tremor. e-book.Frontiers in Clinical Drug Research - CNS and Neurological Disorders; Rhaman, A.U., Ed.; Bentham Science Publishers, 2013, Vol. 2, pp. 110-142.
[http://dx.doi.org/10.2174/9781608057757113020007]

Rights & Permissions Print Cite
Article Metrics
43
4
1
© 2024 Bentham Science Publishers | Privacy Policy